SAN DIEGO, CA — June 21, 2025 — SyntecBio inc, a pioneer in synthetic biology and AI-driven bioprocessing, today announced the launch of new regional headquarters in Singapore and Munich, marking its formal expansion into Asia and Europe. This strategic move enables SyntecBio to deliver its AI-enhanced drug discovery and biomanufacturing platforms closer to key markets and research hubs. By leveraging advanced machine-learning models alongside automated lab systems, the company aims to accelerate R&D timelines and improve global access to scalable, sustainable biotech solutions.
SyntecBio’s proprietary AI-enhanced platform combines predictive compound modeling with robotic automation to streamline every stage of the bioproduction workflow. Researchers can now simulate thousands of biological designs in silico, reducing the need for costly trial-and-error in the lab. With real-time data analytics and closed-loop feedback controls, SyntecBio’s system optimizes yield and purity at unprecedented speed—cutting development cycles by up to 40%.
To support its global rollout, SyntecBio has forged partnerships with BioLab Asia in Singapore and BioM Campus in Germany, securing access to state-of-the-art facilities and local expertise. The company also completed a $75 million Series B funding round led by Horizon Ventures, which will underwrite the build-out of new AI-integration centers and expanded manufacturing capacity. These milestones underscore SyntecBio’s commitment to bringing AI-powered biotech innovations to partners, academic institutions, and biopharma customers worldwide.
“By embedding artificial intelligence at the core of our R&D engine, we’re enabling faster, more accurate biological discoveries with real-world impact,” said Dr. Elena Voss, CTO of SyntecBio. “Expanding into Singapore and Munich positions us to work hand-in-hand with leading research organizations and biomanufacturers, ensuring that life-saving therapies and sustainable materials reach patients and industries at scale.”
The global synthetic biology market is projected to exceed $60 billion by 2030, driven by surging demand for AI-assisted drug design, precision fermentation, and eco-friendly biomanufacturing. SyntecBio’s timely expansion aligns with these industry trends, offering partners end-to-end solutions from discovery through production.
For media inquiries or partnership opportunities, please contact:
Sarah Kim, Director of Communications
[email protected] | +1 (415) 555-2080
Visit: https://syntecbiofuel.com
About SyntecBio
SyntecBio is a global leader in synthetic biology, uniting AI, automation, and microbial engineering to develop scalable biotech solutions for pharmaceuticals, energy, and materials. Headquartered in California with operations across North America, Europe, and Asia, SyntecBio’s mission is to transform how the world discovers and manufactures life-saving medicines and sustainable products.